Abstract
Introduction
Natural Killer (NK) cells exert cytotoxic functions and secrete IFN-c and other pro-inflammatory cytokines against virus-infected and tumor cells. Also, NK cells are key regulators of the adaptive immune response through their cross talk with dendritic cells (DCs) that promotes DC maturation, and T helper (Th) 1-and cytotoxic T lymphocyte (CTL)-mediated immunity [1, 2] . NK cell activity is regulated by cytokines such as interleukin (IL)-2, IL-12, IL-15, IL-18 and type I interferons (IFNs) [3] . NK cell effector function is also triggered upon recognition of target cells through activating receptors such as NKG2D, DNAM-1, 2B4, the Natural Cytotoxicity Receptors (NCRs) NKp46, NKp44 and NKp30, and members of the Killer Immunoglobulin-like Receptor (KIR) family that carry a short cytoplasmic tail (KIR2DS and KIR3DS) [4, 5] . Conversely, normal cells are preserved from NK cell mediated functions because they promote engagement of inhibitory KIR receptors that carry a long cytoplasmic tail (KIR2DL and KIR3DL), CD94/NKG2A and members of the Immunoglobulin-Like Transcript (ILT) receptor family [4, 5] . Human NK cells, defined as CD3 2 CD56 + cells, can be subdivided in two main cell populations. About a 90% are cytotoxic CD56 dim CD16
+ cells, while the remaining 10% are CD56 bright CD16 dim/2 non-cytotoxic cells that are abundant in secondary lymphoid organs [6, 7] . This subpopulation expresses CD62L (L-selectin) and CCR7, which directs their homing to these niches but upon activation, CD62L down-regulation facilitates NK cell trafficking to inflamed tissues [8] .
In vitro evidence indicates that CD56 bright NK cells are precursors of CD56 dim NK cells. However, in vivo evidence about such lineage development is still lacking. As mouse NK cells are different from human NK cells in many aspects [1] , results from knockout mice cannot be extrapolated to humans. Conversely, human NK cell deficiencies are helpful to unravel the immunobiology of NK cells but these conditions are very rare [9] . Absolute or functional NK cell deficiencies are 
Methods
Studies have been approved by the institutional review board and written informed consent was obtained from the parents of the patient (as he was not major at the beginning of these studies). In addition, written consent was obtained from the parents on the behalf of the minors involved in our study as well as from the major healthy volunteers that provided blood samples for this study. Also, all the participants (or the parents of the participants) of this study gave written consent for the publication of the clinical data gathered along this investigation.
Antibodies, cytokines and reagents
Recombinant human IL-2, IL-12 and IL-15 were from PeproTech; recombinant human IL-18 was from MBL International. The following mAbs against human molecules were used: FITC-, PE-and SPRD-labeled anti-CD3 (UCHT-1, Southern Biotech); PE/Cy7-labeled anti-CD3 (UCHT-1, Biolegend); FITC-labeled anti-CD14 (HCD14 Biolegend); PE-labeled anti-HLA class I (W6/32, Biolegend); PE/Cy5-labeled anti-CD56 (N901, Beckman Coulter); FITC-labeled anti-CD16 (eBioCB16, eBioscience); FITC-labeled anti-CD57 (HCD57, Biolegend); FITC-or PE-labeled anti-CD62L (DREG-56, Southern Biotech); FITC-labeled anti-perforin (pfp, dG9, Biolegend); PElabeled anti-IFN-c (4S.B3, Biolegend); FITC-labeled antiCD107a (1D4B, BD Biosciences); PE-labeled anti-CD25 (BC96, Biolegend); FITC-labeled anti-CD69 (FN50, BD); PElabeled anti-NKG2D mAb (clone 1D11, Biolegend); PE-labeled anti-NKp46 (clone 9E2; Biolegend); FITC-labeled anti-CD226 (DNAM-1, clone DX11, BD Pharmingen); PE-labeled anti-CD244 (2B4, clone C1.7, Biolegend); PE-labeled anti CD94 (clone DX22; Biolegend); APC-labeled anti-NKG2A (clone 131411, R&D); mAb isotype-matched control mAb (IC, eBioscience). KIR analysis was performed with a mix of PElabeled anti-CD158a, h (EB6.B) and the anti-CD158b1, b2 (GL183) mAbs (both from Beckman Coulter). For regulatory T cell staining, the Alexa Fluor 488, FoxP3, CD4, CD25 FoxP3 staining kit from BD was used. 7AAD Viability Staining Solution was from Biolegend.
PBMCs and NK cells
Human peripheral blood mononuclear cells (PBMCs) and NK cells were isolated from blood of healthy volunteers or from the patient described in this work (called ''P'') using Ficoll-Paque TM Plus (Amersham Biosciences) centrifugation and the RosetteSep kit (StemCell), respectively. During the initial testing, we recruited age-matched healthy donors to compare the patient with these age-matched samples (hematological data, percentage of NK cells and CD56 dim and C56 bright populations). However, as the values of this age-matched population was similar to the values for adult population, and considering that the patient reached the age of 17 at the end of this study, in subsequent (retroactive) experiments we used healthy donors that correspond to young adults (ages between 25 and 30). Purity of isolated NK cells (CD3 2 CD56 + cells) was above 90%, as assessed by flow cytometry (FC). In some experiments, PBMCs were cultured with IL-2 (0.8 ng/ml) or IL-15 (10 ng/ml) in RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum (NatoCor, Córdoba, Argentina), sodium pyruvate, glutamine and gentamicin (Sigma) for up to 5 days. Flow cytometry and cell sorting Cells were stained with specific fluorochrome-labeled mAbs, analyzed in a FACSAria flow cytometer (BD), and data were processed with the FlowJo software (Tree Star Inc., Ashland, OR). Numerical data presented are the percentage of cells in the quadrants in the dot plots or to the geometric mean fluorescence intensity (MFI) in the histograms. Also, CD3
2 CD56 dim and CD3 2 CD56 bright cells were sorted with the FACSAria cell sorter up to .99% of purity.
IFN-c production by NK cells
PBMCs from normal donors or from the patient were stimulated overnight at 37uC with IL-12 (10 ng/ml), IL-15 (1 ng/ml) and IL-18 (10 ng/ml). During the last 4 h of culture, GolgiStop and GolgiPlug reagents (BD) were added, following the instructions provided by the manufacturer. Thereafter, cells were stained with anti-CD3 and anti-CD56 mAbs, permeabilized with Cytofix/Cytoperm (BD) and stained with the anti-IFN-c mAb to assess IFN-c producing cells within the CD3 2 CD56 dim and CD3
2 CD56 bright NK cell subpopulations by FC.
Degranulation of NK cells
NK cells were cultured overnight at 37uC with IL-12, IL-15 and IL-18 or K562 target cells. During the last 4 h, the anti-CD107a or an IC mAbs were added together with Golgi-Plug and GolgiStop (BD). Thereafter, cells were stained with anti-CD3 and anti-CD56 mAbs, and the percentage of CD107a + cells within the CD3 2 CD56 + or within the CD3 2 CD56 dim cell populations was determined.
Statistical analysis
A paired t-Student test was used to compare expression of NK cell receptors between CD3 2 CD56 dim and CD3 2 CD56 bright cells.
Results

NK cell number and phenotype in blood of a human patient with melanoma and opportunistic fungal infection
We studied a case of a pediatric patient (P) that presented repeated upper airway infections and that at the age of 12 developed an ulcerative spitzoid melanoma in his right ear. Although the melanoma was successfully removed by surgery, one year later the patient presented pneumonia in the lower right lobe, accompanied by fever and bloody stools. A computed tomography (CT) of the chest revealed the presence of an opaque mass (Fig. 1A) for which a lung biopsy was taken (Fig. 1B) . The analysis of this biopsy revealed the presence of Cryptococcus neoformans (Fig. 1C) . The fungal infection was non-invasive, there was no evidence about other infectious agent in the lung to suspect that the cryptococcosis could have been a super-infection or a case of commensalism, and patient was successfully treated with fluconazol. Nonetheless, the fact that within one year the patient suffered from a melanoma and a deep fungal infection in the lung led to the suspicion that the patient might be experiencing some sort of immunodeficiency. Therefore, further immunological studies were performed. Standard laboratory tests (Table 1 ) ruled out classical primary or secondary immunodeficiencies (this patient was HIVnegative). Also, subclasses of IgG (IgG1, IgG2, IgG3 and IgG4), (Fig. 1G) .
Accumulation of CD56 bright NK cells has been observed in certain TAP deficiencies and after treatment with Daclizumab, a humanized anti-CD25 mAb [10] . TAP deficiencies cause reduced expression of HLA class I molecules, but unaltered amounts of HLA class I molecules were detected on T cells and monocytes of this patient (Fig. 1H ). Daclizumab interferes with the IL-2 signaling, which is a pathway necessary to generate regulatory T cells (Treg, CD4 + CD25 + Foxp3 + cells). However, this patient exhibited percentages of CD4 + CD25 + Foxp3 + cells in peripheral blood that were similar to healthy normal donors (Fig. 1I) . Thus, this patient does not seem to exhibit a TAP deficiency and it is unlikely that he exhibits a blockade in the IL-2 signaling pathway.
To (Fig. 4A) . Although it appeared that CD56 bright cells from the patient produced more IFN-c than the healthy controls, the sample size was not enough to decide whether this difference was statistically significant. Besides, these results indicate that the patient's NK cells do not exhibit a defect in the capacity to produce IFN-c. Moreover, NK cells and CD56 dim NK cells of the patient also did not exhibit an alteration in the degranulation capacity (expression of cell surface CD107a) after stimulation of NK cells with IL-12, IL-15 and IL-18 or after co-culture with K562 cells (Fig. 4B) .
These results suggest that this patient exhibits an altered frequency of NK cells, an increase in the absolute numbers of CD56 bright NK cells in blood, and CD56 dim NK cells that exhibit a slightly reduced percentage of terminally differentiated cells (CD57 + CD158 + ) but with unaltered expression of the main receptors involved in NK cell activation (CD16, NKp46, NKG2D and DNAM-1) and regulation (CD94/NKG2A), and in their IFNc production and degranulation in response to cytokines or K562 cells.
Inappropriate in vitro maturation/activation of NK cells in response to cytokines supports in vivo differentiation of CD56 bright cells into CD56 dim cells
Next, PBMCs of the patient were stimulated with IL-2 or IL-15 and expression of the same cell surface markers as in resting NK cells was assessed ( Fig. 5 and Table 2 ). We observed that upon stimulation with IL-2 or with IL-15, CD56 bright NK cells from the patient up-regulated expression of perforin (Fig. 5) , CD25 (the a chain of the high affinity receptor of IL-2, not shown), and CD69 (not shown) in a similar manner as NK cells from healthy donors. However, upon stimulation with these cytokines, CD56
bright NK cells of the patient remained clearly distinguishable from CD56 dim NK cells in the dot plots (compare Fig. 2 to Fig. 5B  and Fig. 5D ). Conversely, it was hard to distinguish the CD56 bright NK cells from the CD56 dim NK cells in healthy donors, appearing both as only one CD56
+ homogeneous cell population.
Moreover, less CD56 dim NK cells from the patient, compared to healthy controls, acquired CD57 and CD158 upon stimulation with IL-2 or IL-15 ( Fig. 5A and 5B, and Fig. 6A ). Also, a substantial fraction of CD56 dim cells showed a reduction in the percentage of CD16 + cells (Fig. 6A and Table 2 ), and less total NK cells and CD56 dim cells from the patient, compared to healthy controls, became CD57 +
CD158
+ upon stimulation with IL-2 or IL-15 (Fig. 5B, Fig. 5E and Fig. 6B ). Overall, these results suggest that in the patient, less NK cells could progress to an activated phenotype and acquire a terminally differentiated phenotype in response to IL-2 or IL-15. In addition, we observed that CD3
2 CD56 bright cells of the patient exhibited a defective downregulation of CD62L upon stimulation with IL-2 (Fig. 5A, Fig. 6C and Table 2 ) that was not due to a slower kinetic of CD62L downregulation as even at prolonged stimulation periods with IL-2 or IL-15, more than 60% of CD3 2 CD56 bright NK cells of the patient while less than 20% of CD3 2 CD56 bright cells from healthy controls remained CD62L + (Fig. 6D ). Of note, the inability to down-regulate CD62L and the sustained high expression of CD56 was not due to apoptosis induction as CD56 bright NK cells remained viable after 5 days of stimulation with IL-15 (not shown). Experiments performed with sorted CD56 dim and CD56 bright NK cells stimulated with IL-2 revealed that both NK cell subpopulations (from the patient and from the healthy control that was simultaneously analyzed) up-regulated CD56 expression (Fig. 5C) In summary, the results presented suggest that this patient exhibits a clinical picture that is compatible with a novel immunodeficiency-like condition characterized by a) low frequency of CD56 dim NK cells in peripheral blood that cannot properly acquire expression of, CD57 and CD158, and maintain expression of CD16 upon stimulation with IL-2 or IL-15; and b) an increase in the frequency and absolute numbers of CD56 bright NK cells that do not down-regulate CD62L upon stimulation with these cytokines. Overall, these data might suggest the existence of a defect that compromises NK cell maturation and activation and support the idea that in vivo CD3 2 CD56 bright cells differentiate into CD3 2 CD56 dim NK cells.
Discussion
NK cells are pivotal players of the immune response against tumors and viruses in humans and mice. Although much information about NK cell lineage development has been obtained using genetically modified animals, information about human NK cell ontogeny is limited mostly due to the scarcity of human NK cell deficiencies. Some data have emerged from studies performed in blood of patients after bone marrow transplantation [11] . Also, four NK cell developmental intermediates have been indentified in human lymph nodes and tonsils [12] [10, [13] [14] [15] [16] [17] [18] , but in vivo evidence is still lacking. Here, we describe the first human immunodeficiency-like Figure 3 . Expression of NK cell receptors. PBMCs from at least 3 different normal(healthy) donors (N) and from different blood draws from different dates (indicated in parentheses) from the patient (P) were stained with anti-CD3, anti-CD56, and anti-CD16, anti-NKp46, anti-NKG2D, anti-DNAM-1, anti-CD94, anti-NKG2A or anti-2B4 as described in Methods. Fluorescence derived from the third fluorochrome-labeled mAb on CD3 [20] [21] [22] [23] [24] , but none of them seem to be plausible in the patient herein studied. Recently, two reports described mutations in the minichromosome maintenance complex component 4 (MCM4) that caused NK cell deficiency and adrenal insufficiency [25, 26] . In one report, reduced NK cell numbers were observed but their phenotype and function was not investigated [26] . In the other report it was observed that the patients that carry the mutation exhibited reduced amounts of CD56 dim NK cells and lower percentages of pfp + , CD57
+ and CD94 med/low/2 NK cells in blood, and it was concluded that CD56 bright NK cells are largely depend on MCM4 to proliferate and generate C56 dim NK cells [25] . However, normal amounts of CD56 bright NK cells in blood of the patients were detected. Conversely, in the patient that we present in this work, a consistent increase in absolute counts of CD56 bright NK cells was detected and he did not exhibit a growth retardation or adrenal insufficiency.
A detailed phenotypic analysis of NK cells from our patient revealed percentages of perforin
+ within the CD56 dim subpopulation, and CD62L + cells within the CD56 bright subpopulation that were similar to healthy donors. However, the patient exhibited slightly decreased percentages of CD57 + CD158 + CD56 dim NK cells. Expression of CD57 and CD158 has been associated with the acquisition of a terminally differentiated phenotype by NK cells [27, 28, 29] for which it appears that the patient presents less terminally differentiated NK cells in peripheral blood. Also, CD56 dim and CD56 bright NK cell subpopulations expressed unaltered amounts of the main receptors involved in NK cell activation (CD16, NKp46, NKG2D and DNAM-1) and regulation (CD94/NKG2A), and did not exhibit a defect in IFN-c production upon stimulation with IL-12, IL-15 and IL-18. Also, CD3
2 CD56 dim NK cells did not present an altered degranulation in response to cytokines and K562 cells. Since we observed a decrease in CD56 dim NK cell frequency with a concomitant increase in the frequency and absolute numbers of CD56 bright NK cells in peripheral blood, we reasoned that the patient may course with a mild immunodeficiency that affects NK [34, 35] . As only CD56 bright NK cells but not CD56 dim NK cells exhibited defective downregulated CD62L, it is very unlikely that the patient may display a defect in these enzymes. CD62L directs the traffic of CD56 bright cells to lymph nodes, where they down-regulate CD62L upon activation, facilitating the migration of NK cells to inflamed tissues. As CD56 bright NK cells from the patient failed to down-regulate CD62L upon stimulation, we suggest that they probably may traffic normally into lymph nodes but once they sense activating stimuli, they may display an altered trafficking pattern due to such faulty down-regulation of CD62L. This situation may lead to a weakened immunosurveillance of peripheral tissues exposed to environmental pathogens (such as skin and mucosa), which could have contributed to the development of a melanoma and the opportunistic fungal infections at these sites.
Of note, as the altered NK cell phenotype and response to cytokines described is partial and a fraction of NK cells from the patient achieved terminal differentiation, we suggest that he carries some sort of mild immunodeficiency or immunodeficiency-like condition that is probably the result of a heterozygous genotype that generates a ''bottleneck'' (instead of a complete blockade) that precludes CD56 dim NK cell development and activation at rates similar to healthy individuals. Such putative heterozygous genotype would preclude normal differentiation of CD56 bright cells to CD56 dim cells and in the acquisition of a CD62L low/2 CD16 + CD57 + CD158 + phenotype by CD56 dim cells but would allow a sufficient number of NK Table 2 . Expression of NK cell markers in CD56dim and CD56bright cells from two healthy normal donors (N1, N2) and from the patient (P). cells to mature adequately and respond to activation stimuli, which in turn would provide a sufficient degree of NK cell activity to protect the patient from suffering major infections, in particular viral infections that are characteristic in patients with absolute or severe functional defects in NK cells [9] . Despite these speculations, our results provide evidence that indicates that in vivo, CD56 bright cells differentiate into CD56 dim NK cells, which constitute a contribution to a better understanding of NK cells ontogeny in humans. Figure 5 . Phenotype of NK cells stimulated with IL-2 or IL-15. PBMCs from two healthy normal donors (N1 and N2) and from the patient (P) (A, B) or sorted CD56 dim and CD56 bright NK cells from one healthy normal donor and from the patient (C) were stimulated for 3 days with IL-2. Also, PBMCs from two healthy normal donors (N1 and N2) and from the patient (P) were stimulated for 3 days with IL-15 (D, E). Thereafter, cells were harvested and stained with anti-CD3 and anti-CD56, and a third fluorochrome-labeled mAb (indicated on the y-axis). Also, expression of CD57 and CD158 in NK cells (gated as CD3 2 CD56 + cells) from N1, N2 and the patient (P), and on CD3 
